ZNF217 and breast cancer: Retrospective analysis of gene-expression array data for 2,978 breast cancer patients revealed that high levels of ZNF217 mRNA expression were strongly and significantly associated with shorter RFS in the luminal subgroup (p = 2.2 × 10−5), but were not prognostic in HER2+ or triple negative subclasses.